Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017

DUBLIN, Oct. 3, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq; JAZZ) today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) on September 30, 2016,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news